Expertise in

conditions

Yoshikazu Inoue

Toyoake, JP

Expertise in

conditions

Toyoake, JP

Overview

Yoshikazu Inoue practices practicing medicine in Toyoake, Japan.

Mr. Inoue is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Pulmonary Alveolar Proteinosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Hepatectomy, and Osteotomy.

He is actively involved in clinical research, co-authoring 280 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Toyoake, Japan

Other Locations

Sakai, 5918555, Japan

Neyagawa, Japan

Chuo, 5918025, Japan

Osaka, Japan

Sakai, Japan

Fujita, Japan

Okazaki, Japan

Chuo, Japan

Amagasaki, Japan

Chuo, 8608556, Japan

Tokyo, Japan

Tosa, Japan

Hiroshima, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Japanese Idiopathic Interstitial Pneumonias Registry

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Enrollment Status: Terminated

Publish Date: September 19, 2024

Intervention Type: Drug

Study Drug: Pamrevlumab

Study Phase: Phase 3

A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan

Enrollment Status: Completed

Publish Date: February 22, 2024

Intervention Type: Other

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Enrollment Status: Completed

Publish Date: December 11, 2023

Intervention Type: Drug, Other

Study Drug: ND-L02-s0201

Study Phase: Phase 2

A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients

Enrollment Status: Completed

Publish Date: April 12, 2023

Intervention Type: Drug, Device

Study Phase: Phase 2

View 4 Less Clinical Trials

280 Total Publications

Host-state biomarkers and clinical factors for stratification and optimization of cell therapy trials in chronic limb-threatening ischemia: A review.

Journal: Regenerative therapy

Published: April 07, 2026

View All 280 Publications

Frequently Asked Questions about Yoshikazu Inoue

Is Yoshikazu Inoue a top-rated expert for Pulmonary Alveolar Proteinosis?

MediFind is an objective health platform that identifies experts based on real-world data. Yoshikazu Inoue is classified as an Elite expert for Pulmonary Alveolar Proteinosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yoshikazu Inoue participate in research or clinical trials?

Yes. Yoshikazu Inoue has published 280 articles and abstracts on conditions like Pulmonary Alveolar Proteinosis. You can view a list of Yoshikazu Inoue's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Inoue's expertise for a condition

ConditionClose